PRESS RELEASE

Junevity Expands Seed Funding to $20 Million for Cell Reprogramming with siRNA

Goldcrest Capital and Godfrey Capital led new funding to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies.

JUN_01 would be the first ever candidate to reprogram metabolism with siRNA, and has demonstrated glucose reduction, insulin sensitization, robust weight loss and dosing once every six months in preclinical studies.

Press release here.